TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reactogenicity assessed by Number of Solicited Systemic Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve (AUC(0-inf))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anastomotic leakage detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Subjects With Any FAP-related Event
Endpoint domain: Adverse events/effects
Primary endpoint: Kappa score of TOFTEE image compared with field grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kappa score of TOFTEE image compared with DSLR grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kappa score of DSLR image compared with field grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Selective Mutism Questionnaire scores over 15 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: arterial oxygenation (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Culture-confirmed pneumococcal acute otitis media episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Global rating of goal-concordant care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Strength Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of acute myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Validation of pediatric Bristol stool scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Days to Achieve Oral Feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of the FiberSense system as compared with laboratory gold standard reference (LGSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of use of the FiberSense system
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of (Serious) Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Biochemical failure free-rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days above toxic anti-GBM antibody titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cytokine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Extended Glasgow Outcome Scale (GOSE)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Intraoperative maximum grip strength (KgF) baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative maximum grip strength (KgF) variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operative Time (Minutes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fecal microbial analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Pharmacokinetics of AG-013736
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of serum bile acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of urine bile acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of serum GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of serum FGF-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quantification of HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Average Pain Score (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intervention fidelity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of seroprotection and geometric mean titers (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline of Venous Serum Bicarbonate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Working Memory Improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of intra-operative catheter related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of post-operative catheter related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of catheter related complications after catheter removal
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of unmet needs
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Immune function (TNF-α, IL-1β, IL-6, TGF-β, IL-8, PCT, CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Caregiver Mastery Pearlin Caregiver Stress Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Transient Ischemic Attack (TIA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Limb Ischemia requiring surgical intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Decrease in Macrophage Derived Suppressor Cells (MDSC) Numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: clinical feasibility rate (CFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static posturography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Receiver Operating Characteristics Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of bevacizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality caused by any reasons in RICU
Endpoint domain: Mortality/survival
Primary endpoint: morbidity caused by any reasons in RICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive functions score change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: safety evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Somatic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patient-reported clinical adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: mean stabilized topiramate dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Urinary Flow Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Body Shape Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24 hours opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visit to the ED, hospital admission or death within 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Expression level of MHC class II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in flow mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacokinetic parameters for pioglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters for rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters for GSK1278863 and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total screening uptake rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sensitivity of 3D power Doppler
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Crow's feet responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality (death)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Trough Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pro-brain natriuretic peptide (proBNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Spherical Equivalent Refractive Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Pain Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Trough Seated Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Work Capacity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Strength of extremity muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Who Were Seroprotected (SPR) for HI Antibodies Against the Flu A/California/7/2009 (H1N1) Virus Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of mTVM on genuine stress incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: working memory (change from baseline)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Discontinuation of metoclopramide therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Glasgow Outcome Scale Extended score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Positive agreement among the positives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced rate from baseline in 24h integrated gastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete removal rate of colorectal polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of recurrent stroke or death
Endpoint domain: Mortality/survival
Primary endpoint: Change in delta overall score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in depressive symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with change in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with change in Electrocardiography (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in endothelial cell density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior opening size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Stability of IOL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of postoperative complication
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Systolic Blood Pressure at 1 Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in High Sensitivity C-Reactive Protein (hsCRP) at 1 Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular profiling of tumor cell populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Radiological features associated with tumor microenvironment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological features associated with tumor microenvironment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of SARS-CoV-2 as determined by negative RT-PCR
Endpoint domain: Mortality/survival
Primary endpoint: Safety as determined by presence or absence of any adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline isometric strength of biceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of benign lung nodules experiencing invasive procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in joint components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants Meeting ACR50 Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Modified Total Sharp Score (mTSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Diameter Stenosis of the Culprit Lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Day 3 fluid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic organ prolapse symptoms score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Major Vascular Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Type 2 Diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: transverse development of the arches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in 60 day post SNF admission outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance in detecting significant obstructive CAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: progression of Radio therapy-induced skin reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants with Hospitalizations Before LAI use
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Participants with Hospitalizations After LAI use
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Early postoperative cognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in sleep latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Participants With Emergence Delirium (ED)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Collection and storage of specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of Combination Chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who complete 3 doses of the HPV vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum observer drug concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration versus time curve (AUC[0-∞])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of cardiac output with transthoracic echocardiography (TTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measure of cardiac output with Physioflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mature oocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Implantation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence and duration of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intensity and severity of AES/SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge related to colorectal cancer screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intentions related to biospecimen donation and clinical trial participation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient response to treatment for dysmenorrhea
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete and Partial Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time needed for fetal head delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cerebral autoregulation monitoring feasibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of participants with treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Extent of periinterventional myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lanza scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tape migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for switching to sphincterotomy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increases in brain glycine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Subjects With ATIII Levels of 58% or Higher at ICU Admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Who Survived to Hospital Admission
Endpoint domain: Mortality/survival
Primary endpoint: Blood markers of muscle damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First impressions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum tolerated dose (MTD) established
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma pharmacokinetics (PK) characterized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Graft Cells Present
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in AUC (Area Under Curve) in C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CYP2D6 activity: dextromethorphan metabolic ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global cognitive composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: safety of 10% Terbinafine HCl Nail Lacquer
Endpoint domain: Adverse events/effects
Primary endpoint: Clinician's Interview-Based Impression of Change (CIBIC-plus)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in hip function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of ENL reactions
Endpoint domain: Adverse events/effects
Primary endpoint: plasma VEGF levels and survival time
Endpoint domain: Mortality/survival
Primary endpoint: urine VEGF levels and survival time
Endpoint domain: Mortality/survival
Primary endpoint: CgA levels and survival time
Endpoint domain: Mortality/survival
Primary endpoint: Lung T1-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tamoxifen and metabolites plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete resolution of major symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Function Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to rehospitalisation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to major therapy adjustment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Medication Possession Ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: corneal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: cup to disc ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Time to Composite of All Cause Mortality and Major Cardiovascular Events
Endpoint domain: Mortality/survival
Primary endpoint: Number of Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in emotional distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing